|5/20/2020||Sales of darolutamide started in the EU and Japan – Orion receives total of EUR 28 million milestones|
|5/14/2020||New ARAMIS Phase III data to be presented at ASCO 2020: Nubeqa® (darolutamide) significantly improved overall survival with a favorable safety profile in men with non-metastatic prostate cancer|
|4/14/2020||Orion publishes Interim Report for January-March 2020 on Tuesday 28 April 2020|
|3/30/2020||Nubeqa® (darolutamide) receives EU approval as a new treatment for men with non-metastatic castration-resistant prostate cancer|
The 2020 Annual General Meeting of Orion was held on Wednesday, 6 May 2020. The decisions and related material are available here.
Orion published Interim Report for January-March 2020 on Tuesday, 28 April 2020. The report, presentation material and link to webcast recording are available here.
|5/25/2020||Change in Orion Group Executive Management Board as of 1 June 2020: Professor Outi Vaarala appointed as Senior Vice President for Research and Development|
|5/6/2020||Orion Corporation: Organising meeting of the Board of Directors|
|5/6/2020||Orion Corporation: Decisions by the AGM on 6 May 2020|
|4/28/2020||Orion Corporation: Change in Orion Group Executive Management Board as of 1 May 2020|
The product and service portfolio of Orion includes a variety of human pharmaceuticals, veterinary drugs, APIs and contract manufacturing.
One key area of Orion's business is Critical Care. Our portfolio includes Simdax® for acute heart failure and Precedex® and Dexdor® for sedation. Read more about Orion's proprietary products and other human pharmaceuticals.
Orion is the largest employer in the Finnish pharmaceutical industry. It is considered to be a good and reliable employer, which is also indicated by its lower-than-average employee turnover.